FDA warned Pharmacy Plus (Vital Care Compounder) that its sterile compounded drugs were made under insanitary conditions, risking contamination.
What happened
FDA inspected the Hattiesburg, MS facility from October 3 to October 13, 2022, and found serious deficiencies in sterile drug production. FDA issued a Form FDA 483 on October 13, 2022. The firm had recalled sterile drugs within expiry on October 7, 2022, because it lacked sterility assurance.
What FDA found
FDA found microbial contamination in the sterile work area (ISO 5) and the firm did not take adequate corrective action.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The laminar airflow hood had dirty, hard-to-clean, particle-generating surfaces, and staff used non-sterile pads and wipes in the sterile work area.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]An operator used a non-sterile tool on and manually touched the inside of a sterile drug container or closure.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]An operator left the sterile work area with gloved hands and re-entered without sanitizing the gloves.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The firm produced hazardous drugs without adequate separation and cleaning to prevent cross-contamination.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]Media fill tests (process simulations) were not run under the most challenging conditions, and smoke studies did not show proper airflow.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
What FDA wants
FDA asks the firm to notify the office in writing within 15 working days of receipt of steps taken to address the violations, with explanations and supporting documents. FDA also strongly recommends a comprehensive assessment of sterile operations with a third-party expert.
Who should pay attention
- patients who receive compounded sterile drugs
- clinics and hospitals that buy compounded sterile products
- pharmacies and compounders with sterile operations
This is a summary. Read the original letter on fda.gov.